Science Tour Health Research in Germany December 4 -10, 2011 Participants
Total Page:16
File Type:pdf, Size:1020Kb
Science Tour Health Research in Germany December 4 -10, 2011 Participants 1 DENMARK “Research in Germany” Science Tour – “Health Research in Germany” POLAND Our world is increasingly being shaped by a globalization process, driven by a knowl- HEIDELBERG STUTTGART MUNICH edge-based economy. Education and research have become powerful forces behind social, economic and cultural developments. The exchange of ideas and academic cooperation are the keys to our mutual welfare and economic growth. In recognition of THE this, the German Federal Government is increasing its investments in research and devel- NETHER- opment and focusing more intensively on internationalizing key future sectors. LANDS European Molecular Fraunhofer Institute Ludwig Maximilians Biology Laboratory for Interfacial University Munich (EMBL) Engineering and (LMU) On the occasion of the Year of Science 2011 “Research for Our Health,” launched Biotechnology (IGB) by the Federal Ministry of Education and Research (BMBF), the German Academic Exchange Service (DAAD) has invited international scientists and administrators to learn more about medical research and graduate education in Germany. During a week- long tour, they will become acquainted with Germany’s unique network of university German Cancer Max Planck and non-university research institutes and their close ties to industry and commerce. The Research Center Institute of program will focus on three highly topical issues in healthcare today: personalized (DKFZ) Biochemistry (MPIB) medicine, neurodegenerative diseases and cancer research. BELGIUM TUEBINGEN The Science Tour 2011 is part of the “Research in Germany – Land of Ideas” campaign, initiated by the BMBF in 2006 to strengthen and expand R&D collaboration between Germany and international partners. The tour, organized by the DAAD on behalf of the Rinecker Proton BMBF, brings German and international researchers together to discuss current develop- Heidelberg Therapy Center ments in health research and to defi ne common areas of interest as starting points for (RPTC) Hertie future cooperation. Institute for Clinical Brain Research CZECH (HIH) Stuttgart The DAAD is the largest funding organisation in the world and supports the international REPUBLIC exchange of students and scholars. Its primary objectives include encouraging outstand- Tuebingen PENZBERG ing academics from abroad to study or conduct research in Germany and enabling FRANCE Munich German researchers to gain professional qualifi cation at the best institutions around the world. For more information on “Research in Germany”, the annual Science Tours and the DAAD, please visit: Penzberg Roche Diagnostics • www.research-in-germany.de GmbH • www.research-in-germany.de/sciencetours SWITZERLAND AUSTRIA • www.daad.de Sunday, December 4, 2011 Monday, December 5, 2011 Arrival in Munich according to individual arrangements Round table discussion and coffee break Moderator Dr. Christian Schäfer Check-in at the Head of Section: Internationalisation of Research Rinecker Proton Therapy Center – RPTC Guesthouse German Academic Exchange Service 5:30 – 7:30 p.m. Welcome address and general introduction (room: 349) High-Tech Campus, guided tour of Gene Center Munich Dr. Christian Schäfer Prof. Dr. Eckhard Wolf Head of Section: Internationalisation of Research Director, Institute of Molecular Animal Breeding and German Academic Exchange Service Biotechnology Anne Knab Group 1: Dr. Helmut Blum Project Offi cer, Section: Marketing for Research Head of Genomics German Academic Exchange Service Laboratory for Functional Genome Analysis (LAFUGA) 7:30 p.m. Walk to the restaurant » Transcriptomics 7:45 – 9:15 p.m. Dinner at the restaurant Zum Flaucher Group 2: Dr. Georg J. Arnold Walk back to the guesthouse Head of Proteomics Laboratory for Functional Genome Analysis (LAFUGA) Program Program Accommodation RPTC Guesthouse, Munich » Proteomics 4 Further participants: 5 Monday, December 5, 2011 Dr. Isolde von Bülow Head of Graduate Center, LMU Munich 8:15 a.m. Transfer Dr. Robert Fürst 9:00 – 12:30 p.m. Biocenter, Ludwig Maximilians University of Munich – LMU Project Leader, Department of Pharmacy, LMU Munich Prof. Dr. Ulrich Pohl Prof. Dr. Olivier Gires Vice President, International Affairs Head of ENT Research and the Clinical Cooperation Group: Welcome and presentation of LMU Munich » Molecular Oncology, LMU Munich Prof. Dr. Patrick Cramer Dr. Matthias Hadesbeck Head of Gene Center Munich, Department of Biochemistry Acting Head of the International Offi ce, LMU Munich » Welcome Dr. Manfred Ogris Prof. Dr. Horst Domdey Group Leader: Vectorology, Department of Pharmacy, LMU Managing Director, BioM Biotech Cluster Development GmbH Munich » “m4 – Munich’s Integrated Approach to Personalized Medicine” Dr. Stephanie Wehnelt International Affairs & Training Prof. Dr. Georg Marckmann, MPH BioM Biotech Cluster Development GmbH Director, Institute of Ethics, History, and Theory of Medicine » “A New Paradigm with Old Challenges? Ethical Implications of Personalized Medicine” Monday, December 5, 2011 Monday, December 5, 2011 Dr. Karin Jacob Dr. Andreas Pichlmair Senior Project Manager m4 Head of the Max Planck Research Group: BioM Biotech Cluster Development GmbH Innate Immunity “Innate Immune Recognition and Stealth Dr. Daniela Tonn » Strategies of Viruses” Manager, International Affairs & Training BioM Biotech Cluster Development GmbH Coffee break Informal discussion 12:30 p.m. Transfer 5:30 – 6:00 p.m. Transfer (1st stop: city center, 2nd stop: hotel) 12:45 p.m. Lunch at Café Freshmaker 7:00 p.m. Transfer 1:40 p.m. Transfer 7:30 – 9:00 p.m. Dinner at the restaurant Hofer – Der Stadtwirt 2:00 – 5:30 p.m. Max Planck Institute of Biochemistry – MPIB Transfer Dr. Ralf Tatzel Assistant to the Board of Managing Directors Accommodation RPTC Guesthouse, Munich » Presentation of the Max Planck Institute of Biochemistry Dr. Andreas Bracher and Dr. Mark Hipp Program Program Program Project Group Leaders Tuesday, December 6, 2011 Research Department: Cellular Biochemistry 6 Checkout 7 “Protein Folding in Health and Disease” » 8:15 a.m. Walk to RPTC Parallel guided lab tours: 8:30 – 9:45 a.m. Rinecker Proton Therapy Center – RPTC Group 1: Prof. Dr. Manfred Herbst Dr. Zuzana Storchova Medical Director Head of the Max Planck Research Group: Medical Executive Board, PROHEALTH AG Maintenance of Genome Stability » Tour of RPTC “Genome, Transcriptome and Proteome » 10:00 – 11:00 a.m. Transfer to Penzberg Dynamics in Aneuploid Cells” 11:15 – 12:45 a.m. Roche Diagnostics GmbH Dr. Roland Wedlich-Söldner Head of the Max Planck Research Group: Dr. Bernhard Skrobranek Cellular Dynamics and Cell Patterning Head of Occupational Safety, Environmental Protection, and » “Microscopy Approaches to Study Cellular Organization” Quality Management Welcome and introduction to Roche’s biotechnology site in Group 2: » Penzberg Dr. Marc Schmidt-Supprian Adrian von Sigriz Head of the Emmy Noether Research Group: Senior Vice President of Global R&D, Roche Applied Science Molecular Immunology and Signal Transduction » Roche Applied Science » “Modeling Oncogenic NF-kB Activation in Mice” Tuesday, December 6, 2011 Wednesday, December 7, 2011 Dr. Ralf Schumacher 8:00 a.m. Transfer to Tübingen Head of Biologics Research and pRED Center Manager 9:30 – 1:00 p.m. Hertie Institute for Clinical Brain Research – HIH Penzberg » Pharma Research and Early Development; Biologics Introduction to the Neurocampus in Tübingen Dr. Friedrich Feuerhake Dr. Annette Klepper Head of Experimental Pathology Head of Department, Structure and Development Planning Pharma Research and Early Development, pRED » Introduction to the University Hospital and the medical » Tissue Biomarkers and Pathology faculty Translational Research Sciences Prof. Dr. Holger Lerche Dr. Christian Meisel Director, Department of Neurology and Epileptology Oncology Site Leader and Head of Translational Executive Board of Directors Medicine Penzberg » Introduction to the Hertie Institute for Clinical Brain Research Pharma Research and Early Development, pRED Prof. Dr. Mathias Jucker » Oncology Research and Early Development Director, Department of Cellular Neurology Dr. Jochen Hurlebaus Executive Board of Directors Introduction to the German Center for Neurodegenerative Head of Central R&D Services – Innovation & Program Program Program » IP Management Diseases 8 » Roche Professional Diagnostics Anita Meier-Kanke 9 12:45 – 2:00 p.m. Lunch and scientifi c exchange in foyer 050 with postdocs from Head of offi ce for EU and international funding schemes, the areas previously introduced technology transfer, invention disclosures, and summer courses Funding possibilities in Germany and the EU 2:00 – 2:15 p.m. Walk to Biologics II » Dr. Simone Di Giovanni 2:15 – 3:45 p.m. Parallel groups: Group Leader, Independent Research Dr. Klaus Reichert » Being an independent research group leader at the Director Downstream Processing Hertie Institute for Clinical Brain Research Group 1: Pegasys fermentation and downstream » Dr. Della David Dr. Marc Preuß Group Leader, Junior Research Plant Manager API » Being a junior research group leader at the German Center » Group 2: Pegasys fermentation and downstream for Neurodegenerative Diseases 3:45 p.m. Coffee break (in the foyer of building 232) Lena Burbulla and Jasmin Hefendehl Presentation of PhD thesis 4:15 p.m. Transfer to Stuttgart via Ulm for dinner » 1:00 – 2:00 p.m. Lunch at the Hertie Institute for Clinical Brain Research 7:15 – 8:30 p.m. Dinner at the restaurant Ratskeller Ulm 10:30